Chronic exposure to MPTP as a primate model of progressive parkinsonism: A pilot study with a free radical scavenger

Experimental Neurology

Volumn 153, Issue 2, 1998, Pages 214-222

  Blanchet, P J ^a   Konitsiotis, S ^a   Hyland, K ^b,c   Arnold, L A ^b   Pettigrew, K D ^d   Chase, T N ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Antioxidant; Monkeys; MPTP; Neuroprotection; Oxidative stress; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; FREE RADICAL; N (7 HYDROXY 2,2,4,6 TETRAMETHYL 1 INDANYL) 4 (3 METHOXYPHENYL) 1 PIPERAZINEACETAMIDE; SCAVENGER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; LONG TERM EXPOSURE; MONKEY; MOTOR ACTIVITY; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSONISM; PREDICTION; PRIORITY JOURNAL;

EID: 0032191183     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1998.6906     Document Type: Article

References (68)

1. Adams J. D. Jr., Odunze I. N. Biochemical mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Could oxidative stress be involved in the brain. Biochem. Pharmacol. 41:1991;1099-1105.
2. Albanese A., Granata R., Gregori B., Piccardi M. P., Colosimo C., Tonali P. Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: Behavioural, morphological and biochemical correlates. Neuroscience. 55:1993;823-832.
3. Ali S. F., David S. N., Newport G. D., Cadet J. L., Slikker W. Jr. MPTP-induced oxidative stress and neurotoxicity are age-dependent: Evidence from measures of reactive oxygen species and striatal dopamine levels. Synapse. 18:1994;27-34.
4. Anglade P., Vyas S., Javoy-Agid F., Herrero M. T., Michel P. P., Marquez J., Mouatt-Prigent A., Ruberg M., Hirsch E. C., Agid Y. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol. 12:1997;25-31.
5. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington: Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20:1973;415-455.
6. Bodis-Wollner I., Chung E., Ghilardi M. F., Glover A., Onofrj M., Pasik P., Samson Y. Acetyl-levo-carnitine protects against MPTP-induced parkinsonism in primates. J. Neural Transm. 3:1991;63-72.
7. Burns R. S., Chiueh C. C., Markey S. P., Ebert M., Kopin I. J. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra byN. Proc. Natl. Acad. Sci. USA. 80:1983;4546-4550.
8. Burns R. S., LeWitt P. A., Ebert M. H., Pakkenberg H., Kopin I. J. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N. Engl. J. Med. 312:1985;1418-1421.
9. Chan P., DeLanney L. E., Irwin I., Langston J. W., Di Monte D. Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain. J. Neurochem. 57:1991;348-351.
10. Chase T. N., Ng L. K. Y. Central monoamine metabolism in Parkinson's disease. Arch. Neurol. 27:1972;486-491.
11. Chase T. N., Engber T. M., Mouradian M. M. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Parkinson's Disease. Advances in Neurology. 69:1996;Lippincott-Raven, Philadelphia. p. 497-501.
12. Chen X. L., Li R., Gupta M. Estrogen may protect females from Parkinson's disease. Soc. Neurosci. Abstr. 21:1995;1252.
13. Chiueh C. C., Wu R.-M., Mohanakumar K. P., Sternberger L. M., Krishna G., Obata T., Murphy D. L. In vivo. Ann. NY Acad. Sci. 738:1994;25-36.
14. Clarke C. E., Boyce S., Sambrook M. A., Crossman A. R. Timing of levodopa therapy: Evidence from MPTP-treated primates. Lancet. 1:1987;625.
15. Cohen G., Pasik P., Cohen B., Leist A., Mytilineou C., Yahr M. D. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. Eur. J. Pharmacol. 106:1985;209-210.
16. Dluzen D. E., McDermott J. L., Liu B. Estrogen alters MPTP-induced neurotoxicity in female mice: Effects on striatal dopamine concentrations and release. J. Neurochem. 66:1996;658-666.
17. Eidelberg E., Brooks B. A., Morgan W. W., Walden J. G., Kokemoor R. H. Variability and functional recovery in theN. Neuroscience. 18:1986;817-822.
18. Furukawa Y., Kondo T., Nishi K., Yokochi F., Narabayashi H. Total biopterin levels in the ventricular CSF of patients with Parkinson's disease: A comparison between akineto-rigid and tremor types. J. Neurol. Sci. 103:1991;232-237.
19. Gerlach M., Riederer P., Przuntek H., Youdim M. B. H. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur. J. Pharmacol. Mol. Pharmacol. Sect. 208:1991;273-286.
20. German D. C., Dubach M., Askari S., Speciale S. G., Bowden D. M. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in Macaca fascicularis: Which midbrain dopaminergic neurons are lost. Neuroscience. 24:1988;161-174.
21. 2. Exp. Neurol. 117:1992;185-188.
22. Gomez-Mancilla B., Boucher R., Gagnon C., Di Paolo T., Markstein R., Bédard P. J. Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors. Movement Dis. 8:1993;144-150.
23. Hantraye P., Varastet M., Peschanski M., Riche D., Cesaro P., Willer J. C., Mazière M. Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons. Neuroscience. 53:1993;169-178.
24. Hassouna I., Wickert H., Zimmermann M., Gillardon F. Increase in bax expression in substantia nigra following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment of mice. Neurosci. Lett. 204:1996;85-88.
25. +. Neuroscience. 40:1991;133-158.
26. Howells D. W., Smith I., Hyland K. Estimation of tetrahydrobiopterin and other pterins in cerebrospinal fluid using reversed phase high performance liquid chromatography with electrochemical and fluorescence detection. J. Chromatogr. 381:1986;285-294.
27. Imbert C., Bezard E., Bioulac B., Dufy B., Gross C. E. A new chronic MPTP model: Validation in monkey and mouse. Soc. Neurosci. Abstr. 23:1997;1654.
28. Irwin I., DeLanney L. E., Forno L. S., Finnegan K. T., Di Monte D. A., Langston J. W. The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey. Brain Res. 532:1990;242-252.
29. Irwin I., Finnegan K. T., DeLanney L. E., Di Monte D. A., Langston J. W. The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: A critical reassessment. Brain Res. 572:1992;224-231.
30. Jenner P., Olanow C. W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology. 47:1996;S161-S170.
31. +. NeuroToxicology. 12:1991;285-302.
32. Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
33. Kish S. J., Shannak K., Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: Pathophysiologic and clinical implications. N. Engl. J. Med. 318:1988;876-880.
34. Kitt C. A., Cork L. C., Eidelberg F., Joh T. H., Price D. L. Injury of nigral neurons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A tyrosine hydroxylase immunocytochemical study in monkey. Neuroscience. 17:1986;1089-1103.
35. Langston J. W. The etiology of Parkinson's disease with emphasis on the MPTP story. Neurology. 47:1996;S153-S160.
36. Leenders K. L., Salmon E. P., Tyrrell P., Perani D., Brooks D. J., Sager H., Jones T., Marsden C. D., Frackowiak R. S. J. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch. Neurol. 47:1990;1290-1298.
37. Levine R. A., Miller L. P., Lovenberg W. Tetrahydrobiopterin in striatum: Localization in dopamine nerve terminals and role in catecholamine synthesis. Science. 214:1981;919-920.
38. LeWitt P. A., Galloway M. P., Matson W., Milbury P., McDermott M., Srivastava D. K., Oakes D. Markers of dopamine metabolism in Parkinson's disease. Neurology. 42:1992;2111-2117.
39. LeWitt P., Bannon M., Galloway M., Kapatos G., Matson W., McDermott M., Oakes D. Monoaminergic metabolism, substance P, met-enkephalin, and biopterin in Parkinson's disease. Neurology. 43:1993;A408.
40. Lovenberg W., Levine R. A., Robinson D. S., Ebert M., Williams A. C., Calne D. B. Hydroxylase cofactor activity in cerebrospinal fluid of normal subjects and patients with Parkinson's disease. Science. 204:1979;624-626.
41. 12. Eur. J. Pharmacol. 253:1994;215-224.
42. Matson W. R., Langlais P., Vollcere L., Gamache P. H., Bird E., Mark K. A. n. Clin. Chem. 30:1984;1477-1488.
43. Mihatsch W., Russ H., Gerlach M., Riederer P., Przuntek H. Treatment with antioxidants does not prevent loss of dopamine in the striatum of MPTP-treated common marmosets: Preliminary observations. J. Neural Transm. 3:1991;73-78.
44. +. Neurosci. Lett. 170:1994;191-194.
45. Mochizuki H., Goto K., Mori H., Mizuno Y. Histochemical detection of apoptosis in Parkinson's disease. J. Neurol. Sci. 137:1996;120-123.
46. Nagatsu T., Yamaguchi T., Kato T., Sugimoto T., Matsuura S., Akino M., Nagatsu I., Iizuka R., Narabayashi H. Biopterin in human brain and urine from controls and parkinsonian patients: Application of a new radioimmunoassay. Clin. Chim. Acta. 109:1981;305-311.
47. Ovadia A., Zhang Z., Gash D. M. Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. Neurobiol. Aging. 16:1995;931-937.
48. N. Engl. J. Med. 328:1993;176-183.
49. Arch. Neurol. 52:1995;237-245.
50. Ann. Neurol. 40:1996;99-107.
51. Perry T. L., Yong V. W., Clavier R. M., Jones K., Wright J. M., Foulks J. G., Wall R. A. Partial protection from the dopaminergic neurotoxinN. Neurosci. Lett. 60:1985;109-114.
52. Pifl C., Schingnitz G., Hornykiewicz O. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience. 44:1991;591-605.
53. Reinhard J. F. Jr., Carmichael S. W., Daniels A. J. Mechanisms of toxicity and cellular resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium in adrenomedullary chromaffin cell cultures. J. Neurochem. 55:1990;311-320.
54. Rose S., Nomoto M., Jenner P., Marsden C. D. Transient depletion of nucleus accumbens dopamine content may contribute to initial akinesia induced by MPTP in common marmosets. Biochem. Pharmacol. 38:1989;3677-3681.
55. Russ H., Mihatsch W., Gerlach M., Riederer P., Przuntek H. Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease. Neurosci. Lett. 123:1991;115-118.
56. Scherman D., Desnos C., Darchen F., Pollak P., Javoy-Agid F., Agid Y. Striatal dopamine deficiency in Parkinson's disease: Role of aging. Ann. Neurol. 26:1989;551-557.
57. Schneider J. S., Kovelowski C. J. II. Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. Brain Res. 519:1990;122-128.
58. 10. Exp. Neurol. 132:1995;279-283.
59. Sershen H., Reith M. E. A., Hashim A., Lajtha A. Protection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity by the antioxidant ascorbic acid. Neuropharmacology. 24:1985;1257-1259.
60. Stern Y., Tetrud J. W., Martin W. R. W., Kutner S. J., Langston J. W. Cognitive change following MPTP exposure. Neurology. 40:1990;261-264.
61. Tatton N. A., Kish S. J. In situ. Neuroscience. 77:1997;1037-1048.
62. Tatton W. G., Ju W. Y. H., Wadia J., Tatton N. A. Reduction of neuronal apoptosis by small molecules: promise for new approaches to neurological therapy. Olanow C. W., Jenner P., Youdim M. Neurodegeneration and Neuroprotection in Parkinson's Disease. 1996;209-220 Academic Press, London.
63. Tohgi H., Abe T., Takahashi S., Takahashi J., Nozaki Y., Ueno M., Kikuchi T. Monoamine metabolism in the cerebrospinal fluid in Parkinson's disease: Relationship to clinical symptoms and subsequent therapeutic outcomes. J. Neural Transm. 5:1993;17-26.
64. Tottori K., Kikuchi T., Uwahodo Y., Nakai M., Miwa T., Hirose T., Fujiwara K., Oshiro Y., Morita S. Protective effects of OPC-14117 on dopaminergic neuronal degeneration induced by MPTP in ICR mice. Jpn. J. Pharmacol. 67:1995;144P.
65. Turkka J. T., Juujärvi K. K., Myllylä V. V. Correlation of autonomic dysfunction to CSF concentrations of noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's disease. Eur. Neurol. 26:1987;29-34.
66. Ueki A., Chong P. N., Albanese A., Rose S., Chivers J. K., Jenner P., Marsden C. D. Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin. Neuropharmacology. 28:1989;1089-1097.
67. Varastet M., Riche D., Mazière M., Hantraye P. Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease. Neuroscience. 63:1994;47-56.
68. Zuddas A., Oberto G., Vaglini F., Fascetti F., Fornai F., Corsini G. U. MK-801 prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in primates. J. Neurochem. 59:1992;733-739.